(Q43687599)

25 November 2017

title

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

1 reference

McKenney JM

1

1 reference

25 November 2017

McCormick LS

2

1 reference

25 November 2017

Schaefer EJ

3

1 reference

25 November 2017

Black DM

4

1 reference

25 November 2017

Watkins ML

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

American Journal of Cardiology

25 November 2017

published in

1 reference

25 November 2017

volume

88

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

270-274

1 reference

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Hypertriglyceridemia as a cardiovascular risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Management of primary hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Management of dyslipidemia in NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901639-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(01)01639-3

1 reference

25 November 2017

1 reference